President Donald J. Trump has signed into law H.R. 5371, the “Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026.”

Passage is welcome news for the sunscreen sector, which has been awaiting changes at U.S. Food and Drug Administration (FDA) that will open the door to new advancements in final formulations.

H.R. 5371 contains full-year funding for the agency.

The full text of H.R. 5371 can be accessed here.

Signage of H.R. 5371 came after a 43-day-long shutdown of the U.S. federal government, the longest in U.S. history.

PCPC’s Statement on H.R. 5371

The Personal Care Products Council (PCPC) issued the following statement regarding H.R 5371:

“The Personal Care Products Council (PCPC) and our member companies applaud the passage of H.R. 5371, which includes full-year funding for the U.S. Food and Drug Administration (FDA). This action ensures that the agency has the necessary resources to safeguard public health and foster innovation.

“We are especially appreciative of the inclusion of measures that reinforce the policy goals of the cosmetics and personal care products industry and reinforce our strong commitment to safety. PCPC is proud to support the reauthorization of the Over-the-Counter Monograph User Fee (OMUFA) program through 2030. The OMUFA reauthorization includes critical language enabling FDA to consider broader evidence when evaluating the safety and efficacy of topical products such as sunscreen. This is a significant step in promoting skin cancer prevention by ensuring U.S. residents have access to innovative and effective sunscreen ingredients. It is also meaningful progress towards the regulatory acceptance of non-animal test methods.

“PCPC is pleased that H.R. 5371 also includes dedicated funding for FDA to implement key provisions of the Modernization of Cosmetics Regulation Act (MoCRA) of 2022, enabling FDA to continue building the infrastructure necessary to support a modernized regulatory framework for cosmetics. This investment is essential to ensure that MoCRA’s science-based mandates—such as facility registration, product listing and safety substantiation—continue to be implemented effectively. The bill also mandates a report to Congress on ongoing rulemakings related to Good Manufacturing Practices and fragrance allergen labeling.

“We appreciate Congress’s attention to these important public health matters, and we look forward to continuing our work with FDA.”